Cost-Effectiveness Analysis of Patiromer in Combination with Renin–Angiotensin–Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden

Objectives Patients with chronic kidney disease (CKD) are commonly treated with renin–angiotensin–aldosterone system inhibitors (RAASi) in order to delay progression of renal disease. However, research has shown that RAASi in CKD patients increases hyperkalaemia (HK) prevalence, which leads to RAASi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PharmacoEconomics 2020-07, Vol.38 (7), p.747-764
Hauptverfasser:	Widén, Julia, Ivarsson, Magnus, Schalin, Lovisa, Vrouchou, Polina, Schwenkglenks, Matthias, Heimbürger, Olof, Ademi, Zanfina, Sutherland, C. Simone
Format:	Artikel
Sprache:	eng
Schlagworte:	ACE inhibitors Age Aging Care and treatment Chronic illnesses Chronic kidney failure Cost analysis Cost benefit analysis Dosage and administration Economic aspects Endocrine system Evaluation FDA approval Health Administration Health Economics Health technology assessment Hyperkalemia Kidney diseases Kidneys Markov chains Medicin och hälsovetenskap Medicine Medicine & Public Health Methods Morbidity Mortality Original Research Article Patients Pharmacoeconomics and Health Outcomes Population Potassium Public Health Quality of Life Research Sensitivity analysis Sodium
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!